NCT02647125View on ClinicalTrials.gov

A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCC

PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

September 30, 2022

Study Completion Date

December 31, 2022

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Huachansu

Huachansu 20 ml/m2/d, intervenous infusion, once a day, 5 times per week, during the period of radiation.

RADIATION

thoracic radiation

A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.

Trial Locations (1)

200032

Fudan Universtiy Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT02647125 - A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCC | Biotech Hunter | Biotech Hunter